



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Protein A-Agarose: sc-2001

PRODUCT

Protein A is provided as an agarose conjugate for use in immunoprecipitation only. The product is provided as 0.5 ml agarose in 2.0 ml PBS buffer with 0.02% azide. Protein A-Agarose is pre-blocked with BSA to reduce non-specific immunoglobulin binding. Sufficient product is provided for 100 immunoprecipitation reactions, to be used at 20 μ l resuspended volume per reaction.

SPECIFICITY

Protein A-Agarose is suitable for immunoprecipitation of mouse IgG_{2a}, IgG_{2b}, and IgA, rabbit IgG, and human IgG₁, IgG₂ and IgG₄.

PROCEDURE

- Incubate cultured cells (80-90% confluent monolayer in 100 mm cell culture plate or approximately 2-5 x 10⁷ suspension cells in flask).
- Add 3 ml ice cold RIPA buffer to cell monolayer and incubate at 4° C for 10 minutes. For suspension cells, add the RIPA buffer to washed cell pellet in a 15 ml conical centrifuge tube.
- Disrupt cells by repeated aspiration through a 21 gauge needle and transfer to a 15 ml conical centrifuge tube.
- Wash cell culture plate with additional 1.0 ml ice cold RIPA buffer and combine with original extract.
- Pellet cellular debris by centrifugation at 10,000 xg for 10 minutes at 4° C. Transfer supernatant to a fresh 15 ml conical centrifuge tube on ice. Preclear lysate (optional step) by adding 1.0 μ g of the appropriate control IgG (normal mouse, rat, rabbit or goat IgG, corresponding to the host species of the primary antibody), together with 20 μ l of resuspended volume of Protein A-Agarose. Incubate at 4° C for 30 minutes.
- Pellet beads by centrifugation at 2,500 rpm (approximately 1,000 xg) for 5 minutes at 4° C. Transfer supernatant (cell lysate) to a fresh 15 ml conical centrifuge tube on ice.
- Transfer 1 ml of the above cell lysate, or approximately 100-500 μ g total cellular protein, to a 1.5 ml microcentrifuge tube. Add 1-10 μ l (i.e., 0.2-2 μ g) primary antibody (optimal antibody concentration should be determined by titration) and incubate for 1 hour at 4° C.
- Add 20 μ l of resuspended volume of Protein A-Agarose. Cap tubes and incubate at 4° C on a rocker platform or rotating device for 1 hour to overnight.
- Collect immunoprecipitates by centrifugation at 2,500 rpm (approximately 1,000 xg) for 5 minutes at 4° C. Carefully aspirate and discard radioactive supernatant.
- Wash pellet 4 times with 1.0 ml RIPA buffer (more stringent) or PBS (less stringent), each time repeating centrifugation step above.
- After final wash, aspirate and discard supernatant and resuspend pellet in 40 μ l of 1x electrophoresis sample buffer.
- Boil samples for 2-3 minutes and analyze 20 μ l aliquots by SDS-PAGE and autoradiography. Unused samples may be stored at -20° C.
- Optional: After boiling, samples may be centrifuged to pellet the agarose beads followed by SDS-PAGE analysis of the supernatant.

STORAGE

Store at 4° C, do not freeze; stable for one year from the date of shipment.

SELECT PRODUCT CITATIONS

1. Yu, H., et al. 1996. Activation of a novel calcium-dependent protein-tyrosine kinase. Correlation with c-Jun N-terminal kinase but not mitogen-activated protein kinase activation. *J. Biol. Chem.* 271: 29993-29998.
2. Roberts, R., et al. 1997. Altered phosphorylation and intracellular distribution of a (CUG)_n triplet repeat RNA-binding protein in patients with myotonic dystrophy and in myotonin protein kinase knockout mice. *Nature* 94: 13221-13226.
3. Alemu, E.A., et al. 2010. Transforming growth factor- β -inducible early response gene 1 is a novel substrate for atypical protein kinase Cs. *Cell. Mol. Life Sci.* 68: 1953-1968.
4. Koch, D., et al. 2011. Proper synaptic vesicle formation and neuronal network activity critically rely on syndapin I. *EMBO J.* 30: 4955-4969.
5. Zhao, X.Y., et al. 2011. Synergistic induction of galectin-1 by CCAAT/enhancer binding protein α and hypoxia-inducible factor 1 α and its role in differentiation of acute myeloid leukemic cells. *J. Biol. Chem.* 286: 36808-36819.
6. Wang, K., et al. 2011. Quercetin induces protective autophagy in gastric cancer cells: involvement of Akt-mTOR- and hypoxia-induced factor 1 α -mediated signaling. *Autophagy* 7: 966-978.
7. Beebe, J.S., et al. 2003. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. *Cancer Res.* 63: 7301-7309.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

IMMUNOPRECIPITATION REAGENTS

PRODUCT	SPECIFICITY	CAT. #	AMOUNT
Protein A-Agarose	mouse IgG _{2a} , IgG _{2b} and IgA rabbit polyclonal Abs human IgG ₁ , IgG ₂ and IgG ₄	sc-2001	2.0 ml
Protein G PLUS-Agarose	mouse IgG ₁ , IgG _{2a} , IgG _{2b} and IgG ₃ rat IgG ₁ , IgG _{2a} , IgG _{2b} and IgG _{2c} rabbit and goat polyclonal Abs human IgG ₁ , IgG ₂ , IgG ₃ and IgG ₄	sc-2002	2.0 ml
Protein A/G PLUS-Agarose	all of the above Abs	sc-2003	2.0 ml
Protein L-Agarose	mouse, rat, human IgG, scFv and Fab fragments, mouse and human IgM, IgE and IgA	sc-2336	2.0 ml

Immunoprecipitation agarose conjugates are pre-blocked with BSA to reduce non-specific immunoglobulin binding and are provided at a concentration (0.5 ml agarose/2.0 ml) suitable for use at 20 μ l per immunoprecipitation reaction. Number of reactions: 100.



The Power to Question

SAFETY DATA SHEET

Santa Cruz Biotechnology, Inc.

Revision date 20-Nov-2017

Version 1

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

Product identifier

Product Name Protein A-Agarose
Product Code SC-2001

Recommended use of the chemical and restrictions on use

For research use only. Not intended for diagnostic or therapeutic use.

Details of the supplier of the safety data sheet

Santa Cruz Biotechnology, Inc.
10410 Finnell Street
Dallas, TX 75220
831.457.3800
800.457.3801
scbt@scbt.com

Emergency telephone number

Chemtrec
1.800.424.9300 (Within USA)
+1.703.527.3887 (Outside USA)

2. HAZARDS IDENTIFICATION

This chemical is not considered hazardous by the 2012 OSHA Hazard Communication Standard (29 CFR 1910.122).

Classification

Not a dangerous substance or mixture according to the Globally Harmonized System (GHS)

Label elements

Signal word Not classified
Hazard statements Not classified
Symbols/Pictograms Not classified

Precautionary Statements - Prevention Wash hands thoroughly after handling
Precautionary Statements - Response IF exposed or concerned: Get medical advice/attention

Hazards not otherwise classified (HNOC)

Hazards not otherwise classified (HNOC) Not applicable

Other Information

Unknown acute toxicity 100% of the mixture consists of ingredient(s) of unknown toxicity.

NFPA	Health hazards	-		HMIS	Health hazards	-
	Flammability	-			Flammability	-
	Stability	-			Physical hazards	-
	Physical and chemical properties	-			Personal protection	-

3. COMPOSITION/INFORMATION ON INGREDIENTS

Molecular Weight No information available
Formula No information available

Chemical Name	CAS No	Weight %	Oral LD50	Dermal LD50	Inhalation LC50
PBS with Azide	-	70 - 90	-	-	-

Protein A-Agarose	-	10 - 30	-	-	-
-------------------	---	---------	---	---	---

4. FIRST AID MEASURES

First Aid Measures

General advice	Consult a physician if necessary. Remove to fresh air.
Eye contact	Wash with plenty of water.
Skin Contact	Wash skin with soap and water.
Inhalation	Remove to fresh air If breathing is difficult, give oxygen If not breathing, give artificial respiration
Ingestion	Never give anything by mouth to an unconscious person. Clean mouth with water.

Most important symptoms and effects, both acute and delayed

Symptoms No information available.

Indication of any immediate medical attention and special treatment needed

Note to physicians Treat symptomatically.

5. FIRE-FIGHTING MEASURES

Suitable Extinguishing Media

Suitable Extinguishing Media	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Unsuitable Extinguishing Media	None.

Specific hazards arising from the chemical

Specific hazards arising from the chemical	No information available.
Hazardous combustion products	No information available.

Explosion data

Sensitivity to Mechanical Impact	No information available.
Sensitivity to Static Discharge	No information available.

Protective equipment and precautions for firefighters

Protective equipment and precautions for firefighters As in any fire, wear self-contained breathing apparatus pressure-demand, MSHA/NIOSH (approved or equivalent) and full protective gear.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures

Personal precautions Ensure adequate ventilation, especially in confined areas.

Environmental precautions

Environmental precautions See Section 12 for additional Ecological Information.

Methods and material for containment and cleaning up

Methods for containment	Prevent further leakage or spillage if safe to do so.
Methods for cleaning up	Pick up and transfer to properly labeled containers.

7. HANDLING AND STORAGE

Precautions for safe handling

Advice on safe handling Handle in accordance with good industrial hygiene and safety practice.

Conditions for safe storage, including any incompatibilities

Storage Conditions Keep containers tightly closed in a dry, cool and well-ventilated place. Store at 4 °C.
 Incompatible materials None known based on information supplied.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION**Control parameters**

Exposure Guidelines This product, as supplied, does not contain any hazardous materials with occupational exposure limits established by the region specific regulatory bodies.

Appropriate engineering controls

Engineering Controls Showers
 Eyewash stations
 Ventilation systems

Individual protection measures, such as personal protective equipment

Eye/face protection Wear safety glasses with side shields (or goggles).
 Skin and Body Protection Wear protective gloves and protective clothing.
 Respiratory protection If exposure limits are exceeded or irritation is experienced, NIOSH/MSHA approved respiratory protection should be worn. Positive-pressure supplied air respirators may be required for high airborne contaminant concentrations. Respiratory protection must be provided in accordance with current local regulations.
 General Hygiene Considerations Handle in accordance with good industrial hygiene and safety practice.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State liquid
 Appearance No information available
 Odor No information available

Property

Values
 pH No information available
 Melting point/freezing point No information available
 Boiling point No information available
 Flash point No information available
 Density No information available
 Evaporation rate No information available
 Upper flammability limits No information available
 Lower flammability limit No information available
 Vapor pressure No information available
 Vapor density No information available
 Specific gravity No information available
 Water solubility No information available
 Solubility in other solvents No information available
 Partition coefficient No information available
 Autoignition temperature No information available
 Decomposition temperature No information available
 Kinematic viscosity No information available
 Explosive properties No information available
 Oxidizing properties No information available

10. STABILITY AND REACTIVITY

Reactivity	Not applicable
Chemical stability	Stable under recommended storage conditions.
Possibility of Hazardous Reactions	None under normal processing.
Hazardous polymerization	No information available.
Conditions to avoid	Extremes of temperature and direct sunlight.
Incompatible materials	Strong oxidizing agents.
Hazardous Decomposition Products	None known based on information supplied.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation	No data available.
Eye contact	No data available.
Skin Contact	No data available.
Ingestion	No data available.

Information on toxicological effects

Symptoms	No information available.
----------	---------------------------

Delayed and immediate effects as well as chronic effects from short and long-term exposure

Chronic Toxicity	No information available.
------------------	---------------------------

Numerical measures of toxicity - Product Information

Unknown acute toxicity	100% of the mixture consists of ingredient(s) of unknown toxicity
------------------------	---

12. ECOLOGICAL INFORMATION

Ecotoxicity	May cause long lasting harmful effects to aquatic life
-------------	--

100% of the mixture consists of components(s) of unknown hazards to the aquatic environment.

Persistence and degradability	No information available.
Bioaccumulation	No information available.
Mobility	No information available.

13. DISPOSAL CONSIDERATIONS

Disposal of wastes	Disposal should be in accordance with applicable regional, national and local laws and regulations.
Contaminated packaging	Do not reuse container.

14. TRANSPORT INFORMATION

DOT	Not regulated
IMDG	Not regulated

IATA Not regulated

15. REGULATORY INFORMATION

International Inventories

All of the components in the product are on the following Inventory lists

No information available

X - Listed

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List

EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

ENCS - Japan Existing and New Chemical Substances

IECSC - China Inventory of Existing Chemical Substances

KECL - Korean Existing and Evaluated Chemical Substances

PICCS - Philippines Inventory of Chemicals and Chemical Substances

US Federal Regulations

SARA 313

Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1986 (SARA). This product does not contain any chemicals which are subject to the reporting requirements of the Act and Title 40 of the Code of Federal Regulations, Part 372.

SARA 311/312 Hazard Categories

Acute health hazard	No
Chronic Health Hazard	No
Fire hazard	No
Sudden release of pressure hazard	No
Reactive hazard	No

CWA (Clean Water Act)

This product does not contain any substances regulated as pollutants pursuant to the Clean Water Act (40 CFR 122.21 and 40 CFR 122.42).

US State Regulations

California Proposition 65

This product does not contain any Proposition 65 chemicals.

U.S. State Right-to-Know Regulations

This product does not contain any substances regulated by state right-to-know regulations

16. OTHER INFORMATION

Revision note No information available

Disclaimer

The information provided in this Material Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

End of Safety Data Sheet